The WTA acknowledges the decision by the International Tennis Integrity Association (ITIA) — which administers the Tennis Anti-Doping Program (TADP) — in issuing a one-month suspension to Iga Swiatek, following the identification of a contaminated regulated medication (melatonin) as the source for her positive test for the prohibited substance Trimetazidine.
The WTA fully supports Iga during this difficult time. Iga has consistently demonstrated a strong commitment to fair play and upholding the principles of clean sport, and this unfortunate incident highlights the challenges athletes face in navigating the use of medications and supplements.
The WTA remains steadfast in our support for a clean sport and the rigorous processes that protect the integrity of competition. We also emphasize that athletes must take every precaution to verify the safety and compliance of all products they use, as even unintentional exposure to prohibited substances can have significant consequences.
We will continue to work closely with our athletes to provide education and resources that empower athletes to make informed decisions and maintain the highest standards of integrity in our sport.
